Alzheimer's disease is one of the major challenges for today's society. More than 100 million people will be suffering from this disease in 2050 1.
New drugs capable of slowing the progress of Alzheimer's are being actively developed.
Their effectiveness depends on early initiation of treatment, before the disease has the opportunity to progress.
Biocross is a biotech company that investigates new ways of diagnosing Alzheimer's.
Our approach is different from those of other companies, as it combines several types of biomarkers found in blood. This allows for a more accurate diagnosis than currently available diagnostic techniques.
Legal Disclaimer - Designed by Colibri Advertising - Produced by CBE Productions